Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

Erstveröffentlichung

2017

Autoren

Seymour, John F.

Döhner, Hartmut

Butrym, Aleksandra

Wierzbowska, Agnieszka

Selleslag, Dominik

et al.

Wissenschaftlicher Artikel

Erschienen in

BMC Cancer ; 17 (2017). - Art.-Nr. 852. - ISSN 1471-2407

Link zur Veröffentlichung

https://dx.doi.org/10.1186/s12885-017-3803-6

Institutionen

UKU. Klinik für Innere Medizin III

Schlagwörter

[Freie Schlagwörter]: Azacitidine | Low-dose cytarabine | Acute myeloid leukaemia | AML | Myelodysplasia-related changes | AML-MRC | Induction chemotherapy | Response | Survival | independent prognostic relevance | world-health-organization | multilineage dysplasia | morphologic dysplasia | classification | reproducibility | cytogenetics | mutations | neoplasms
[DDC Sachgruppe]: DDC 610 / Medicine & health

Metadata

Zur Langanzeige